Trial Profile
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 16 Mar 2024 Planned End Date changed from 30 Jun 2023 to 15 Mar 2025.
- 16 Mar 2024 Planned primary completion date changed from 30 Jun 2023 to 15 Mar 2025.
- 16 Jun 2022 Planned End Date changed from 1 May 2022 to 30 Jun 2023.